Longevity Drug Development

Developing longevity drugs to extend human lifespan, based on research showing significant life extension in other organisms.

Key Points:

• Addressing underinvestment in aging research
• Leveraging existing research:
  • Drugs like rapamycin extend lifespan in mice by 10-30%
  • Gene knockouts in certain organisms lead to longer lifespans
• Potential for developing drugs that:
  • Mimic gene knockouts
  • Upregulate certain genes
• Goal: Extend healthy human lifespan by 30-50 years

Challenges:

• Lack of funding compared to other medical research areas
• Regulatory framework:
  • FDA historically lacked definition for aging drugs
  • Aging not considered a disease, but a natural state
• Need to define endpoints for clinical trials

Opportunity:

• Underfunded area with potential for significant societal impact
• Possibility to develop high-margin drugs in an industry dominated by cost-plus pricing